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Figure1. a) Clinical system with large uncertainty and overall poor 
quality, b) Clinical system with reduced uncertainty and improved 
clinical benefit (quality) for the majority of treated patients. 
Figure 1 b) shows an outcome distribution for a system with improved 
quality.  In this situation, the vast majority of patients fall in the 
clinical benefit region and the overall uncertainty of clinical outcomes 
is reduced.  The quality improvement in radiation therapy can be 
defined as an effort to move a clinical system from the situation in 
Figure 1 a) to that shown in Figure 1 b).  This quality improvement 
and consistent operational level can be achieved through systems 
management, standardization, benchmarking, and a variety of 
industrial tools.  High level of quality and reliability cannot be 
achieved without a systematic approach to operations and clinical 
management.  In many aspects, Figure 1 is overly simplistic  
representation of the actual clinical operations and other concerns 
like timely and efficient care, cost,and the overall employee and 
patient satisfaction are not considered in this example.  Systematic 
approach to clinical decisions and operational management can lead 
to improvements in all of these areas.  In fact, most modern 
radiotherapy operations are very complex, have a relatively high risk 
for catastrophic failures, and involve significant cost and as such meet 
the very definition of operations which require systems 
approach. Direct translation of industrial methods to clinical 
environment is typically inappropriate and requires adaptation to 
result in meaningful improvements in clinical operations.    
This presentation will discuss: 
1) The role of quality and safety in radiation therapy 
2) Modern approaches to quality management which are adoptable to 
radiation therapy operations 
3) The role of automation, decision support, and knowledge based 
tools for management of safety and quality in radiation therapy 
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Over the past few years, due to the development of new radiotherapy 
equipments and complex techniques such as IMRT, IGRT and IMAT, the 
amount of quality controls (QC) required to check the equipment 
performance and the patient-specific treatment plans has increased 
and could be a barrier to the development of these techniques. 
Although we can find reports or guidelines regarding the procedures, 
protocols and detectors that are best adapted for each control, it 
remains difficult to find discussions on how to improve the dose 
delivery process by reducing variability and by defining action levels. 
In this purpose, we suggest that the quality control results should not 
only be analyzed in an individual manner by checking if the result is 
within predefined tolerances, but should also be analyzed from a 
process behaviour point of view. This is done by evaluating the 
position of the current result compared to all of the previous similar 
results. This will help to detect a potential drift of the whole process 
that could be missed when evaluating each result individually. As a 
consequence, this will help to increase quality. To perform this 
process analysis, an industrial method: the Statistical Process Control 
(SPC) has been used. SPC aims at controlling and improving the quality 
of a process through statistical analysis, by using two main tools: 
control charts and performance indices. 
Control charts (see Figure 1) are graphics that monitor the process 
over time, by using statistical control limits that distinguish random 
(natural) variations (i.e values within the control limits) from 
significant changes (special causes) that disturb the process. Thanks 
to the statistical control limits, the effects of special causes can be 
detected, and then actions can be undertaken to reduce or eliminate 
their effects. A process that is only subject to random causes of 
variation around the target value (i.e the perfect value to which each 
result should tend to, for instance having 0% of deviation between 
calculation and measurement) is statistically under control and thus 
statistically predictable.  
Performance indices quantify the ability of a process to produce data 
that are within predefined tolerances, at a precise moment. They give 
a value showing how far the results are from these tolerances and/or 
from the target. So, contrary to control charts, performance indices 
depend on the tolerances that are often chosen empirically, based on 
practice and experience, and thus on the QC’s method.  
In the presentation, we will show how SPC can be used to monitor the 
IMRT pre-treatment quality controls and to make the dose delivery 
process under control. The aim is to increase the security of each 
patient’s treatment while controlling the whole dose delivery process, 
without increasing time devoted to the analysis. 
We are convinced that SPC should help to secure and to improve 
quality of many processes in radiotherapy and could serve as a 
common language to evaluate processes’ performance. Moreover, the 
ultimate goal of SPC is, considering a process is under control, to 
streamline the amount of QC in a safe statistical environment by 
taking objective decisions to balance resources and quality. 
 Figure 1: Example of a control chart displaying three potential special 
causes. This process is out of control. 
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It has been estimated (UNSCEAR, 2000) that there are worldwide 
about 2000 million X-Ray studies, 32 million nuclear medicine studoes 
and over 6 million radiation therapy treated annually, and the 
numbers are constantly increasing. 
The process of radiotherapy (RT) is complex and involves 
understanding of the principles of medical physics, radiobiology, 
radiation safety, dosimetry,radiation treatment planning, simulation 
and interaction of radiation with other treatment modalities. Each 
step in the integrated process of RT needs quality control and quality 
assurance (QA) to prevent errors and to give high confidence that 
patients will receive the prescribed treatment correctly.Recent 
advances in RT, including intensity-modulated and image-guided RT, 
focus on the need for a systematic RTQA program that balances 
patient safety and quality with available resources. It is necessary to 
develop more formal error mitigation and process analysis methods, 
such as failure mode and effect analysis, to focus available QA 
resources optimally on process components. External auditprograms 
for RT can serve to improve patient safety and quality of care, 
andthus are also effective; these can be found in some national or 
international regulatory authorities and professional societies. 
In addition to an on-site audit, an off-site audit, such as a postal 
dosimetry audit program, is necessary to assure the dose from RT 
equipment. For more than three decades, some international 
authorities and national/continental professional societies have 
operated some independent dosimetry audits (postal 
thermoluminescent dosimetry (TLD) or radiochromic films dose-
auditing programme) for more than 2000 RT institutions in 120 
countries. A global and steady improvement in the performance of 
dosimetry audits has been occurring so that ~95% of the participating 
institutions are within the 5% acceptance limit for beam calibration. 
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Several countries have adopted the IAEA’s method to establish their 
own national auditing networks. Further development is being 
considered to check not only the reference condition, i.e.beam 
calibration, but also non-reference conditions, such as irregularly 
shaped and wedged beams, rotational, helical or not intensity 
modulated RT beams(Table), proton therapy beams. 
 
Reference Region Average SD (%) 
Gillis et al., 2005 
ESTRO-QUASIMODO 
Europe 1.014 
0.997 
1.6 
3.6 
Tomsej et al., 2005 
GORTEC 
Europe 0.992 3.9 
Ibott et al., 2006 
RPC-RTOG 
US 0.99 
0.99 
8 
7 
Tomsej et al., 2007 
ESTRO-OECI 
Europe 0.966 
0.978 
2.4 
1.5 
 
ESTRO booklet 9 Guidelines for the verification of IMRT, Table 7.3: 
Results from studies of the accuracy of dose determinations of IMRT 
treatments. 
Recent advances in radiotherapy focus on the need for a systematic 
quality assurance program that balances patient safety and quality 
with available resources. External audit programmes for radiotherapy 
QA are also effective. Both postal dosimetry audit and clinical trial 
radiotherapy QA, especially for advanced technologies, in 
collaboration with global networks, will serve to enhance patient 
safety and quality of care. 
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Purpose/Objective: The accuracy of photon dose calculation in the 
out-of-field regions is often neglected despite its importance for 
organs at risk and peripheral dose evaluation. The present work 
assessed the dose calculation accuracy of the Anisotropic Analytical 
Algorithm (AAA) and the Acuros XB algorithms implemented in the 
Eclipse treatment planning system, in the regions shielded by the jaw, 
or the MLC, or both MLC and jaw for flattened (6 and 10 MV) and 
unflattened (6 and 10 FFF MV) beams. The largest difference to out-
of-field dose coming from the two beams (flattened and unflattened) 
is due to the head scatter, where for FFF beams a lower contribution 
is expected due to the lack of flattening filter scattering. 
Materials and Methods: Six and 10 MV, flattened and unflattened 
beams, were from a TrueBeam (Varian Medical Systems, Palo Alto, 
USA), equipped with Millennium 120-MLC. Depth doses in water, out of 
the field, parallel to the field edge were acquired at 1, 2, 3, 5 and 10 
cm distance from the field edge. Lateral field side was set as 1, 5 and 
10 cm. The following shielding modalities were used to set the beam: 
(1) jaw defined field (MLC retracted); (2) MLC defined field (jaws set 
to 40x35 cm2); (3) jaw+MLC defined field (both positioned at the field 
edge). Measurements were acquired with a 0.125 cm3 ion chamber. All 
measurements were then compared with the corresponding AAA and 
Acuros XB calculations (version11.0.21) in water. 
Four volumetric modulated arc therapy plans (in the RapidArc form) 
were optimized in a water equivalent phantom, PTW Octavius, in a 
way to have a region always shielded by the MLC or jaw+MLC during 
the delivery. A structure was delineated mimicking the target with 
the anterior part of a ring shape of 6 cm external diameter and 3 and 
4 cm thickness (two optimizations); the organ to spare was a 
cylindrical volume at distance of 0.5 cm from the target and with a 
radius of 2 and 1 cm, respectively. Doses to seven points located in 
the shielded region and in the target like structure were measured 
with a 0.125 cm3 ion chamber. Results were compared with the AAA 
and Acuros XB calculations in terms of absorbed dose in a volume as 
the ion chamber sensitive volume.  
Results: In general a good agreement between calculation and 
measurements was found for both algorithms. From depth dose 
analysis the 10 FFF beam resulted, as expected, to offer the lowest 
out-of-field dose. The overall average difference (all energies and 
shielding methods) between measurements and calculations were 
below 0.6% for AAA and below 0.8% for Acuros XB. 
From RapidArc plans analysis the average differences between 
calculation and measurement in the shielded region were -0.9%±0.4% 
and -3.1%±1.3% for AAA and Acuros XB, respectively, relative to the 
mean target dose value. Differences in the target structure were of -
0.5%±2.3%, -0.7%±2.3% for AAA and Acuros XB, respectively. 
Conclusions: The high accuracy required to properly evaluate the out-
of-field dose can be achieved with the analysed algorithms, AAA and 
Acuros XB that showed an accuracy degree in those low dose regions 
similar, relatively to in-field dose, to what obtained for open beams.  
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Purpose/Objective: Assessment of acceptable target dose conformity 
in plans with multiple prescription levels is a challenge due to the 
inevitable over/underdosage at the borderline between dose levels. 
Here, we propose a tool for the evaluation of target dose in treatment 
plans with multiple dose levels, providing a possible contribution to 
level 3 reporting in ICRU report 83. We illustrate the potential of the 
tool in identifying a single plan as suboptimal and identifying a 
systematic change in planning priorities in our institution between 
2010 and 2012. 
Materials and Methods: Dose painted treatment plans with five dose 
levels (DP plans) were evaluated for 20 head and neck cancer 
patients. As a complement to structure specific dose parameters, plan 
specific parameters describing the target dose were used for the 
quality assessment tool. The quality value Q was the basis for the 
evaluation and was used to obtain quality volume histograms (QVH): 
  
A one-dimensional measure, the quality factor, QF, has previously 
been used1 to evaluate target dose: 
 where n is the number of voxels and Qp is the qualityvalue in voxel p. 
We propose to supplement this measure with a 2D QVH tool that is 
based on the experience from previous similar treatment plans. For 
each Q value, the median relative volume, V, and interquartile range 
(iqr) among the group of historical plans was found. An area on the 
QVH corresponding to median(V) ±1.45*iqr was outlined, which in case 
of normal distribution includes 95% of the plans. When evaluating the 
QVH of a new plan, this tool can be used to identify poorer than usual 
dose conformity. We overlaid the QVH plots of 13 clinical 
hypopharyngeal plans from 2010 with 13 hypopharyngeal plans from 
2012, and used the QVH tool to identify a change in plans over time. 
Results: Figure 1 illustrates that one of 20 H&N DP plans was 
identified as suboptimal by the QVH tool, even though it met all 
planning constraints. The plan had more overdosage than what should 
be expected, and was reoptimized and improved (Figure 1, thick dark 
line). The plan QF decreased from 0.056 to 0.045, corresponding well 
to the group average: mean QF 0.047 (range 0.039-0.056). 
Comparison of the 2010 and 2012 plans with the QVH tool clearly 
demonstrated that current treatment plans have less underdosage at 
the expense of more overdosage when compared to the 2010 plans. 
This change is not associated with a change in QF. 
